Press Releases
March 2, 2023
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 1, 2023
Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials
March 1, 2023
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
February 28, 2023
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
February 22, 2023
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
February 16, 2023
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
February 2, 2023
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 4, 2023
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2023
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
December 20, 2022